SIGN UP
LOG IN
News
SYRS
4.720
-7.63%
-0.390
Weekly Report: what happened at SYRS last week (0408-0412)?
Weekly Report · 3d ago
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
NASDAQ · 6d ago
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
NASDAQ · 04/10 17:19
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
NASDAQ · 04/10 12:30
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
U.S. Stocks traded lower toward the end of trading on Tuesday. The Dow traded down 0.46% while the NASDAQ fell 0.24%. The S&P 500 fell around 0.4% and European shares closed lower. Real estate shares jumped by 0.8% in Asian markets. The NFIB Small Business Optimism Index declined for a third straight month.
Benzinga · 04/09 18:34
Syros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for Tamibarotene
Syros Pharmaceuticals shares rose 20% after winning fast-track designation for its drug candidate in certain patients with acute myeloid leukemia. The stock recently traded at $5.42 and is down about 30% for the year to date. The company's drug candidate is for the treatment of certain patients.
Dow Jones · 04/09 18:09
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session. The company missed third-quarter estimates and said it no longer expects to generate positive free cash flow for the full fiscal year 2024. Laser Photonics Corporation shares climbed 168% to $3.82.
Benzinga · 04/09 17:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.0% to $10.16 during Tuesday's regular session. BioSig Technologies stock increased by 27.41% and Tilray Brands stock decreased by 19.5%. The company's Q4 earnings report came out yesterday.
Benzinga · 04/09 16:31
Syros jumps on FDA fast track tag for leukemia drug
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded higher on the news that the FDA granted its fast-track designation for the company's leukemia drug. The drug, tamibarotene, is being investigated for use in patients with acute myeloid leukemia aged 75 years and older.
Seeking Alpha · 04/09 15:00
Fast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid Leukemia
NASDAQ · 04/09 11:29
Syros Gets FDA Fast-Track Designation for Tamibarotene
Syros Pharmaceuticals has won fast-track designation for its drug candidate in certain patients with acute myeloid leukemia. The company says the designation covers the treatment of newly diagnosed patients with RARA gene overexpression. Syros is currently conducting a Phase 2 study of the drug candidate.
Dow Jones · 04/09 11:19
SYROS PHARMACEUTICALS INC: EXPECTS TO REPORT ADDITIONAL DATA FROM SELECT-AML-1 IN 2024
Reuters · 04/09 11:00
SYROS RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR TAMIBAROTENE FOR THE TREATMENT OF NEWLY DIAGNOSED UNFIT AML WITH RARA GENE OVEREXPRESSION
Reuters · 04/09 11:00
Weekly Report: what happened at SYRS last week (0401-0405)?
Weekly Report · 04/08 09:01
Syros Pharmaceuticals Price Target Maintained With a $13.00/Share by Piper Sandler
Dow Jones · 04/03 16:12
Piper Sandler Reiterates Overweight on Syros Pharmaceuticals, Maintains $13 Price Target
Benzinga · 04/03 16:02
Syros Pharmaceuticals (SYRS) Receives a Buy from Piper Sandler
TipRanks · 04/03 11:06
Syros Pharmaceut: Statement of changes in beneficial ownership of securities
Press release · 04/03 01:05
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Syros Pharmaceuticals announced the grant of a restricted stock unit award for 8,400 shares of Syros common stock to one newly hired employee. The award was granted as a material inducement to employment. Syros is committed to developing new standards of care for the frontline treatment of hematologic malignancies.
Barchart · 04/02 15:30
Top 3 Health Care Stocks You'll Regret Missing This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Syros Pharmaceuticals, Inc. Posted weaker-than-expected fourth-quarter results. The company's stock fell around 19% over the past five days. The RSI is a momentum indicator that compares a stock's strength to its price action.
Benzinga · 04/02 12:01
More
Webull provides a variety of real-time SYRS stock news. You can receive the latest news about Syros Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).